CD27 agonism alone and with an PD1 checkpoint inhibitor has also been explored as a potential mechanism of increasing the efficacy of tumor-specific peptide vaccines by enhancing CD4+ helper T-cell and CD8+ cytotoxic T-cell response following vaccination (73, 74). The gene discussed is CD8A; the disease is neoplasm.